natgillin/translations-raw huggingface dataset:
There was insufficient data in patients with severe renal impairment (CLcr &lt; 30 ml/min) to assess its effect on pharmacokinetics (see sections 4.2 and 4.4).
Nedovoljno je podataka u bolesnika s teškim oštećenjem bubrega (CLcr &lt; 30 ml/min) kako bi se procijenio utjecaj na farmakokinetiku (vidjeti dijelove 4.2 i 4.4).
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medications (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), ne morfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medications (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), nemorfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m2 compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), ne morfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m2 compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), nemorfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), ne morfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolešću (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), nemorfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), nemorfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolešću (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), ne morfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease related medications (p=0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), ne morfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was less use of morphinic analgesic (p &lt; 0.01), non-morphinic analgesics (p &lt; 0.01), other disease related medications (p=0.06) and radiotherapy (p &lt; 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Manje su se davali morfinski analgetici (p &lt; 0,01), nemorfinski analgetici (p &lt; 0,01), ostali lijekovi povezani s bolesti (p=0,06) i radioterapija (p &lt; 0,01) bolesnicima koji su se liječili docetakselom 75 mg/m2 nego onima iz skupine BSC.
There was no apparent difference in efficacy for entecavir based on gender (≈ 25% women in the clinical trials) or age (≈ 5% of patients &gt; 65 years of age).
Nije bilo vidljive razlike u djelotvornosti entekavira na temelju spola (≈ 25% žena u kliničkim ispitivanjima) ili dobi (≈ 5% bolesnika u dobi od &gt; 65 godina).
There was no evidence of benefit (no reduction in the primary composite endpoint of CV death, MI and stroke, but an increase in major bleeding) when ticagrelor 60 mg twice daily was introduced in clinically stable patients &gt; 2 years from the MI, or more than one year after stopping previous ADP receptor inhibitor treatment (see also section 4.2).
Nije bilo dokaza o koristi (bez smanjenja primarnog kompozitnog ishoda kadriovaskularne smrti, IM i moždanog udara, ali povećanje velikog krvarenja) kada se tikagrelor u dozi od 60 mg dvaput dnevno primjenjivao u klinički stabilnih bolesnika koji su imali IM prije &gt; 2 godine, ili više od godinu dana nakon prekida liječenja prethodnim inhibitorom ADP receptora (također vidjeti dio 4.2).
There was no evidence of period, sequence/carry-over effects in the ASCEND-PD study (p-values all &gt; 0.10).
Nije bilo dokaza o periodičnim učincima sekvence/prijenosa za ispitivanje ASCEND-PD (sve p-vrijednosti &gt; 0,10).
There was no increase after the second dose whether the children received half of the adult or the adult dose, except for some side effects which were higher after the second dose, particularly for rates of fever in &lt; 6 years old children.
Neovisno o tome jesu li djeca primila pola doze ili cijelu dozu za odrasle, nije zabilježeno povećanje učestalosti nakon druge doze, osim kod nekih nuspojava koje su se javljale češće nakon druge doze, što se osobito odnosi na učestalost vrućice u djece mlađe od 6 godina.
There was no increase after the second dose whether the children received half of the adult or the adult dose, except for some side effects which were higher after the second dose, particularly for rates of fever in &lt; 6 years old children.
Neovisno o tome jesu li djeca primila pola doze ili cijelu dozu za odrasle, nije zabilježeno povećanje učestalosti, osim kod nekih nuspojava koje su se javljale češće nakon druge doze, što se osobito odnosi na učestalost vrućice u djece mlađe od 6 godina.
There was no increased incidence of serious infections observed in patients with lymphocyte counts
Nije bila zabilježena povećana incidencija ozbiljnih infekcija u bolesnika s brojem limfocita &lt; 0,8x109/l ili
There was no significant difference between seroconversion rates in subjects aged &lt; 50 years compared to those aged ≥50 years at Day 28 or Day 56 for either treatment group.
U ispitanika u dobi &lt; 50 godina u odnosu na one u dobi ≥ 50 godina 28. ili 56. dana nije bilo značajne razlike između stopa serokonverzije ni u jednoj skupini liječenja.
There was one ALK-positive patient &gt; 85 years old out of 154 patients in single-arm Study 1001 (see also section 4.2 and 5.2).
Od 154 bolesnika u Ispitivanju 1001 s jednom skupinom bolesnika jedan je ALK-pozitivni bolesnik bio u dobi &gt; 85 godina (vidjeti također dio 4.2 i 5.2).
There was the reduction of relative risk of recurrent myocardial infarction by 35% compared to treatment with unfractionated heparin (p &lt; 0.001).
Zabilježeno je i smanjenje relativnog rizika za reinfarkt miokarda za 35 %, u usporedbi s liječenjem nefrakcioniranim heparinom (p &lt; 0,001).
There was the reduction of relative risk of recurrent myocardial infarction by 35% compared to treatment with unfractionated heparin (p &lt; 0.001).
Zabilježeno je i smanjenje relativnog rizika za reinfarkt miokarda za 35%, u usporedbi s liječenjem nefrakcioniranim heparinom (p &lt; 0,001).
There were 10 new virologic failures between the Week 48 primary analysis and Week 96 (3 patients with baseline viral load ≤ 100,000 copies/mL and 7 patients with baseline viral load &gt; 100,000 copies/mL).
Bilo je 10 novih viroloških neuspjeha između primarne analize 48. tjedna i 96. tjedna (3 bolesnika s početnim virusnim opterećenjem ≤ 100 000 kopija/ml i 7 bolesnika s početnim virusnim opterećenjem &gt; 100 000 kopija/ml).
There were 10 new virologic failures between the week 48 primary analysis and week 96 (3 patients with baseline viral load ≤ 100,000 copies/mL and 7 patients with baseline viral load &gt; 100,000 copies/mL).
Od primarne analize u 48. tjednu do 96. tjedna bilo je 10 novih slučajeva virološkog neuspjeha (3 pacijenata s početnim virološkim opterećenjem ≤ 100 000 kopija/ml i 7 pacijenata s početnim virološkim opterećenjem &gt; 100 000 kopija/ml).
There were 23 patients (4.4%) with a QTc increase from baseline &gt; 60 msec.
Bilo je 23 bolesnika (4,4%) s povećanjem QTc-a &gt; 60 msec u odnosu na početnu vrijednost.
There were 60 patients in the combined Phase 3 studies who were predominantly using controlled-release levodopa (i.e. &gt; 50% of their levodopa/DDCI formulations), 48 of whom were treated solely with controlled-release formulations of levodopa.
Bilo je 60 bolesnika iz kombinirane faze 3 ispitivanja koji su pretežno koristili levodopu s kontroliranim oslobađanjem (tj. &gt; 50% njihovih formulacija levodope/DDCI), 48 ih je bilo liječeno samo formulacijama levodope s kontroliranim otpuštanjem.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %).
Uključen je ograničen broj bolesnika s teškom osnovnom bolešću, poput imunokompromitiranih bolesnika, bolesnika s APACHE II bodovima &gt; 15 (3,3%) ili kirurški verificiranim višestrukim intraabdominalnim apscesima (11,4%).
There were higher rates of Grade 4 neutropenia (ANC &lt; 0.5 x 109/l), 12 % vs 5 %, and thrombocytopenia ( &lt; 20 x 109/l ), 9 % vs 3 %, in women vs men in the first cycle of therapy.
U prvom ciklusu terapije učestalost neutropenije (ABN &lt; 0,5 x 109/l) i trombocitopenije ( &lt; 20 x 109/l) stupnja 4 bila je viša u žena nego u muškaraca: 12% naspram 5% kod neutropenije i 9% naspram 3% kod trombocitopenije.
There were higher rates of Grade 4 neutropenia (ANC &lt; 0.5 x 109/l), 12 % vs 5 %, and thrombocytopenia ( &lt; 20 x 109/l), 9 % vs 3 %, in women vs men in the first cycle of therapy.
U prvom ciklusu terapije stope neutropenije (ABN &lt; 0,5 x 109/l) i trombocitopenije ( &lt; 20 x 109/l) stupnja 4 bile su više u žena nego u muškaraca: 12 % naspram 5 % kod neutropenije i 9 % naspram 3 % kod trombocitopenije.
There were higher rates of Grade 4 neutropenia (ANC &lt; 0.5 x 109/l), 12 % vs 5 %, and thrombocytopenia ( &lt; 20 x 109/l), 9 % vs 3 %, in women vs men in the first cycle of therapy.
U prvom ciklusu terapije učestalost neutropenije (ABN &lt; 0,5 x 109/l) i trombocitopenije ( &lt; 20 x 109/l) stupnja 4 bila je viša u žena nego u muškaraca: 12% naspram 5% kod neutropenije i 9% naspram 3% kod trombocitopenije.
There were more days without any apnoea under caffeine citrate treatment (3.0 days, versus 1.2 days for placebo; p=0.005); also, there was a higher percentage of patients with no apnoeas for &gt; 8 days (caffeine 22% versus placebo 0%).
Bilo je više dana bez apneje uz liječenje kofeincitratom (3,0 dana nasuprot 1,2 dana uz placebo; p=0,005); također, postotak bolesnika bez apneja bio je viši tijekom &gt; 8 dana (kofein 22% nasuprot placebo 0%).
There were no ROS1-positive patients &gt; 85 years old in Study 1001.
Nije bilo ROS1-pozitivnih bolesnika starijih od 85 godina u Ispitivanju 1001.
Thereby, increasing the risk of extreme sedation and respiratory depression from these agents. (For caution on parenterally administered midazolam, see section 4.5).
Time se povećava rizik od ekstremne sedacije i depresije dišnog sustava izazvane tim lijekovima. (Za mjere opreza pri parenteralnoj primjeni midazolama vidjeti dio 4.5).
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m2.
Stoga se preporučuje 50%-tno smanjenje dnevne doze održavanja ako je klirens kreatinina &lt; 60 ml/min/1,73 m2.
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73m2.
Stoga se preporučuje 50%-tno smanjenje dnevne doze održavanja ako je klirens kreatinina
Therefore ambrisentan must not be initiated in patients with severe hepatic impairment, or clinically significant elevated hepatic aminotransferases (greater than 3 times the Upper Limit of Normal ( &gt; 3xULN); see sections 4.3 and 4.4).
Zbog toga se terapija ambrisentanom ne smije započinjati u bolesnika s teškim oštećenjem jetre ili klinički značajnim povišenjem jetrenih aminotransferaza (više od 3 puta iznad gornje granice normalnih vrijednosti ( &gt; 3 x GGN); vidjeti dijelove 4.3 i 4.4).
Therefore ambrisentan should not be initiated in patients with severe hepatic impairment or clinically significant elevated hepatic aminotransferases ( &gt; 3xULN) (see sections 4.3 and 4.4).
Stoga se ne preporučuje uvođenje ambrisentana u bolesnika s teškim oštećenjem jetre ili klinički značajnim porastom jetrenih aminotransferaza ( &gt; 3 x GGN) (vidjeti dio 4.3 i 4.4).
Therefore close monitoring is recommended in patients weighing &lt; 50 kg.
Preporučuje se pažljivo nadzirati bolesnike koji teže manje od 50 kg.
Therefore hepatic aminotransferases (ALT and AST) should be evaluated prior to initiation of ambrisentan and treatment should not be initiated in patients with baseline values of ALT and/or AST &gt; 3xULN (see section 4.3).
Stoga je potrebno prekontrolirati vrijednosti jetrenih aminotransferaza (AST i ALT) prije uvođenja ambrisentana te liječenje ne treba započinjati u bolesnika u kojih su početne vrijednosti ALT i/ili AST &gt; 3xGGN (vidjeti dio 4.3).
Therefore it is assumed that steady-state could be reached earlier in patients &lt; 3 years of age (see section 4.2 for dosing recommendations).
Stoga se pretpostavlja da se stanje dinamičke ravnoteže može postići ranije u bolesnika mlađih od 3 godine (vidjeti dio 4.2 za preporuke za doziranje).
Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to &lt; 18 years and weighing at least 40 kg without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l (see section 4.2).
Stoga se isto doziranje od jedanput na dan može primijeniti kod adolescenata koji su prethodno liječeni u dobi od 12 do &lt; 18 godina s težinom najmanje 40 kg, koji nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM)* a imaju plazmatsku HIV-1 RNK &lt; 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 106/l (vidjeti dio 4.2).
Therefore, a careful benefit-risk assessment is needed when Truvada is used in patients with creatinine clearance &lt; 60 mL/min, and renal function should be closely monitored.
Stoga je potrebna oprezna procjena odnosa koristi i rizika kad se Truvada primjenjuje u pacijenata s klirensom kreatinina &lt; 60 mL/min i treba pažljivo pratiti funkciju bubrega.
Therefore, a safe and effective dosage recommendation for patients &lt; 1 year old has yet to be established.
Stoga u tih bolesnika u dobi &lt; 1 godine tek treba ustanoviti sigurnu i djelotvornu preporučenu dozu.
Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance &gt; 80 mL/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili acetilsalicilatne kiseline u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance &gt; 80 ml/min).
Stoga je nužan oprez kada se bolesnicima s normalnom bubrežnom funkcijom (klirens kreatinina &gt; 80 ml/min) daju više doze NSAIL-a ili acetilsalicilatne kiseline istodobno s pemetreksedom.
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance &gt; 80 ml/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili acetilsalicilatne kiseline u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance &gt; 80 ml/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili aspirina u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, due to the risk of haemorrhage, notably with NSAIDs with elimination half-lives &gt; 12 hours, close observation for signs of bleeding is recommended (see section 4.4).
Stoga se, zbog rizika od krvarenja, osobito uz NSAIL-e s poluvijekom eliminacije &gt; 12 sati, preporučuje pažljiv nadzor znakova krvarenja (vidjeti dio 4.4).
Therefore, if signs of OHSS occur such as serum oestradiol level &gt; 5,500 pg/ml or &gt; 20,200 pmol/l and/or ≥ 40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days.
Stoga, ako se pojave simptomi OHSS-a kao što su razina estradiola u serumu &gt; 5500 pg/ml ili &gt; 20 200 pmol/l i/ili ≥ 40 folikula ukupno, preporučuje se prestanak davanja hCG-a, a pacijentica se treba suzdržavati od spolnog odnosa ili upotrebljavati barijerne metode kontracepcije najmanje 4 dana.
Therefore, if signs of ovarian hyperstimulation occur such as serum estradiol level &gt; 5,500 pg/mL (20,000 pmol/L) and/or when there are 30 or more follicles in total, it is recommended to withhold hCG administration and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days.
Stoga, ako se pojave znaci hiperstimulacije jajnika kao što je razina serumskog estradiola &gt; 5500 pg/ml (20 000 pmol/l) i/ili u slučaju postojanja ukupno 30 ili više folikula, preporučuje se ukidanje primjene hCG-a, a pacijentici savjetuje suzdržavanje od snošaja ili primjenu barijerne metode kontracepcije tijekom najmanje 4 dana.
Therefore, if signs of ovarian hyperstimulation occur such as serum oestradiol level &gt; 5,500 pg/mL or &gt; 20,200 pmol/L and/or ≥ 40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days.
Stoga, ako se pojave simptomi sindroma hiperstimulacije jajnika, kao što su razina estradiola u serumu &gt; 5500 pg/ml ili &gt; 20 200 pmol/l i/ili ≥ 40 folikula ukupno, preporučuje se prestanak davanja hCG, a pacijentica se treba suzdržavati od spolnog odnosa ili upotrebljavati barijerne metode kontracepcije najmanje 4 dana.
Therefore, it is recommended that children and adolescent patients receiving IntronA/ribavirin combination be discontinued from therapy if their week 12 HCV-RNA dropped &lt; 2 log10 compared to pretreatment, or if they have detectable HCV-RNA at treatment week 24.
Zato se preporučuje obustaviti liječenje u djece i adolescenata koji primaju kombinaciju IntronA/ribavirin ako im razina HCV-RNK u 12. tjednu padne za &lt; 2 log10 u odnosu na vrijednost prije liječenja ili ako imaju mjerljivu razinu HCV-RNK u 24. tjednu liječenja.
Therefore, it is recommended that children and adolescent patients receiving PegIntron/ribavirin combination be discontinued from therapy if their week 12 HCV-RNA dropped &lt; 2 log10 compared to pretreatment or if they have detectable HCV-RNA at treatment week 24.
Zato se preporučuje obustaviti liječenje u djece i adolescenata koji primaju kombinaciju PegIntron/ribavirin ako im HCV-RNK u 12. tjednu padne za &lt; 2 log10 u odnosu na vrijednost prije liječenja ili ako imaju mjerljivu HCV-RNK u 24. tjednu liječenja.
Therefore, it is recommended that children and adolescent patients receiving ViraferonPeg/ribavirin combination be discontinued from therapy if their week 12 HCV-RNA dropped &lt; 2 log10 compared to pretreatment or if they have detectable HCV-RNA at treatment week 24.
Zato se preporučuje obustaviti liječenje u djece i adolescenata koji primaju kombinaciju ViraferonPeg/ribavirin ako im HCV-RNK u 12. tjednu padne za &lt; 2 log10 u odnosu na vrijednost prije liječenja ili ako imaju mjerljivu HCV-RNK u 24. tjednu liječenja.
Therefore, it is recommended that nasogastric, nasojejunal or gastrostomy tubes only be used to administer doses &gt; 1 ml.
Stoga se preporučuje uporaba nazogastrične, nazojejunalne sonde ili gastrostome samo za primjenu doza &gt; 1 ml.
Therefore, it should not be used in patients with baseline haemoglobin &gt; 13 g/dl.
Stoga se Retacrit ne smije koristiti kod bolesnika s početnom razinom hemoglobina &gt; 13 g/dl.
Therefore, the canagliflozin dose should be limited to 100 mg once daily in patients with eGFR &lt; 60 mL/min/1.73 m2 or CrCl &lt; 60 mL/min and canagliflozin should not be used in patients with an eGFR &lt; 45 mL/min/1.73 m2 or CrCl &lt; 45 mL/min (see section 4.2).
Stoga se u bolesnika s eGFR &lt; 60 mL/min/1,73 m2 ili CrCl &lt; 60 mL/min doza kanagliflozina mora ograničiti na 100 mg jedanput dnevno, a kanagliflozin ne smiju uzimati bolesnici s eGFR &lt; 45 mL/min/1,73 m2 ili CrCl &lt; 45 mL/min (vidjeti dio 4.2).
Therefore, the use of pemetrexed in patients with creatinine clearance of &lt; 45 mL/min is not recommended (see section 4.2).
Stoga se primjena pemetrekseda u bolesnika s klirensom kreatinina &lt; 45 ml/min ne preporučuje (vidjeti dio 4.2).
Therefore, the use of pemetrexed in patients with creatinine clearance of &lt; 45 ml/min is not recommended (see section 4.2).
Stoga se primjena pemetrekseda u bolesnika s klirensom kreatinina &lt; 45 ml/min ne preporučuje (vidjeti dio 4.2).
Therefore, the use of pemetrexed in patients with creatinine clearance of &lt; 45ml/min is not recommended (see section 4.2).
Stoga se primjena pemetrekseda u bolesnika s klirensom kreatinina &lt; 45 ml/min ne preporučuje (vidjeti dio 4.2).
Therefore, there are not sufficient data to recommend the use of MEPACT in patients &gt; 30 years of age.
Stoga nema dovoljno podataka da bi se preporučila primjena lijeka MEPACT kod bolesnika starijih od 30 godina.
Therefore, this medicinal product must not be used in patients with moderate to severe renal impairment (patients with CrCl &lt; 60 ml/min or estimated glomerular filtration rate [eGFR] &lt; 60 ml/min/1.73 m2; see section 4.3).
Stoga se ovaj lijek ne smije primjenjivati u bolesnika s umjerenim do teškim oštećenjem bubrežne funkcije (bolesnici s CrCl &lt; 60 ml/min ili procijenjenom brzinom glomerularne filtracije [eGFR] &lt; 60 ml/min/1,73 m2; vidjeti dio 4.3).